DP Medical becomes first NHS Trust to adopt ZedScan as part of cervical cancer care pathway

DP Medical Ltd has secured a deal with Sheffield Teaching Hospitals NHS Foundation Trust (STHFT) to become the first NHS Trust in the country to adopt ZedScan™ as part of its cervical cancer care pathway.

The ground-breaking system, which includes its patented Electrical Impedance Spectroscopy technology, offers quicker and more accurate detection of cervical neoplasia delivering results in real-time, enabling clinicians to improve patient management.

ZedScan enables clinicians to make more informed decisions at a patient’s first visit, thus benefiting both the patient and hospital. The system allows for a more efficient pathway and reduced morbidity for the patient.

The Trust has signed a three-year contract with DP Medical to supply the system which comprises of  a handheld device, software and disposable sensors. This follows the evaluation of over 400 patients at Sheffield Teaching Hospitals NHS Foundation Trust where the ZedScan system was routinely used within a clinical setting.

ZedScan was developed by Zilico Ltd, which includes Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield as partners. Both organisations were pivotal to the product’s development and commercialisation.

Rob Atkinson, UK Business Development Manager and ZedScan product specialist for DP Medical said:

This is a really momentous step for the way patients are managed within the cervical cancer care pathway and we’re delighted that STHFT is the first trust to have fully adopted ZedScan.

Ensuring NHS clinicians have access to the best technology to improve diagnosis in this area of healthcare is vital - and ZedScan certainly meets that criteria.

We are now looking forward to sharing the results of the case study from STHFT to encourage other Trusts around the country to consider adopting ZedScan.

Sir Andrew Cash, Chief Executive of Sheffield Teaching Hospitals NHS Foundation Trust, said:

We pride ourselves on being at the forefront of healthcare innovation and this news reinforces our status as pioneers in new medical technology – particularly as this was a system developed together at the University of Sheffield and our Trust. The ZedScan system has the potential to improve diagnosis and care for patients within the cervical cancer pathway– and I’m delighted it has been developed and adopted here in Sheffield first.

Source: http://www.sth.nhs.uk/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Zilico. (2014, October 17). DP Medical becomes first NHS Trust to adopt ZedScan as part of cervical cancer care pathway. News-Medical. Retrieved on October 08, 2024 from https://www.news-medical.net/news/20141017/DP-Medical-becomes-first-NHS-Trust-to-adopt-ZedScan-as-part-of-cervical-cancer-care-pathway.aspx.

  • MLA

    Zilico. "DP Medical becomes first NHS Trust to adopt ZedScan as part of cervical cancer care pathway". News-Medical. 08 October 2024. <https://www.news-medical.net/news/20141017/DP-Medical-becomes-first-NHS-Trust-to-adopt-ZedScan-as-part-of-cervical-cancer-care-pathway.aspx>.

  • Chicago

    Zilico. "DP Medical becomes first NHS Trust to adopt ZedScan as part of cervical cancer care pathway". News-Medical. https://www.news-medical.net/news/20141017/DP-Medical-becomes-first-NHS-Trust-to-adopt-ZedScan-as-part-of-cervical-cancer-care-pathway.aspx. (accessed October 08, 2024).

  • Harvard

    Zilico. 2014. DP Medical becomes first NHS Trust to adopt ZedScan as part of cervical cancer care pathway. News-Medical, viewed 08 October 2024, https://www.news-medical.net/news/20141017/DP-Medical-becomes-first-NHS-Trust-to-adopt-ZedScan-as-part-of-cervical-cancer-care-pathway.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Two Staffordshire hospitals introduce pioneering technology to improve cervical cancer diagnosis